Article
Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes.
Nature medicine - 1 May 2018
Chapuy Bjoern, Stewart Chip, Dunford Andrew J, Kim Jaegil, Kamburov Atanas, Redd Robert A, Lawrence Mike S, Roemer Margaretha G M, Li Amy J, Ziepert Marita, Staiger Annette M, Wala Jeremiah A, Ducar Matthew D, Leshchiner Ignaty, Rheinbay Ester, Taylor-Weiner Amaro, Coughlin Caroline A, Hess Julian M, Pedamallu Chandra S, Livitz Dimitri, Rosebrock Daniel, Rosenberg Mara, Tracy Adam A, Horn Heike, van Hummelen Paul, Feldman Andrew L, Link Brian K, Novak Anne J, Cerhan James R, Habermann Thomas M, Siebert Reiner, Rosenwald Andreas, Thorner Aaron R, Meyerson Matthew L, Golub Todd R, Beroukhim Rameen, Wulf Gerald G, Ott German, Rodig Scott J, Monti Stefano, Neuberg Donna S, Loeffler Markus, Pfreundschuh Michael, Trümper Lorenz, Getz Gad, Shipp Margaret A
Abstract excerpt
Diffuse large B cell lymphoma (DLBCL), the most common lymphoid malignancy in adults, is a clinically and genetically heterogeneous disease that is further classified into transcriptionally defined activated B cell (ABC) and germinal center B cell (GCB) subtypes. We carried out a comprehensive genetic analysis of 304 primary DLBCLs and identified low-frequency alterations, captured recurrent mutations, somatic...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.